Story perspectives

FDA OKs Zyn Pouches as Lower-Risk, Youth Use Rises

8/9/2026

Summary

Story summary

On June 30, the U.S. FDA allowed Zyn to market 20 nicotine pouches as lower-risk than cigarettes for several diseases.
Researchers said nicotine is addictive with unclear health impacts, and the FDA noted the pouches are not approved cessation aids.
The 2025 Youth Tobacco Survey found 1.7% of students used nicotine pouches—up from 1.1% in 2022—with 90% using flavored varieties, and experts warned the lower-risk claim could mislead young non-smokers.

1 of 1

Story summary

On June 30, the U.S. FDA allowed Zyn to market 20 nicotine pouches as lower-risk than cigarettes for several diseases.
Researchers said nicotine is addictive with unclear health impacts, and the FDA noted the pouches are not approved cessation aids.
The 2025 Youth Tobacco Survey found 1.7% of students used nicotine pouches—up from 1.1% in 2022—with 90% using flavored varieties, and experts warned the lower-risk claim could mislead young non-smokers.